⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31248586 | 0.74 | — | — | |
| SCHEMBL20176026 | 0.72 | — | — | |
| SCHEMBL4892828 | 0.72 | — | — | |
| SCHEMBL28879050 | 0.72 | — | — | |
| SCHEMBL20176032 | 0.65 | — | — | |
| SCHEMBL410240 | 0.64 | — | — | |
| SCHEMBL14488509 | 0.64 | — | — | |
| SCHEMBL9720159 | 0.64 | — | — | |
| SCHEMBL4735310 | 0.62 | — | — | |
| SCHEMBL28919471 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977995-A | Macrocyclic derivatives and their use | 广州嘉越医药科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119859155-A | Tri-fused ring derivative inhibitor, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119522225-A | Macrocyclic derivatives and their use | 广州嘉越医药科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-118871430-A | DNA polymerase theta inhibitors and uses thereof | 西藏海思科制药有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118684662-A | Pyrrolopyridone-containing compounds | 正大天晴药业集团股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-118619921-A | Pyrrolidone structure-containing compounds | 正大天晴药业集团股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-116375683-A | Diazole derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-07-04 | — | — | CN | disclosed |